Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors. Dr. Navid Rabiee, Ph.D., is a leading scientist with over 42,000 citations and an H-index of 72. He integrates molecular and cellular biology with engineering to design advanced medical systems. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. Also, he is the pioneer in developing high-gravity synthesis methods for porous (in)organic nanomaterials to follow the green chemistry principles, which led to the foundations of a new field called “Green Biomaterials”. With 300+ peer-reviewed articles in top journals (including Nature, Nature Medicine, Advanced Materials, The Lancet), 9 books, and 20+ chapters, his work advances medical treatment and sustainable practices.

• Section I: Cancer treatment and challenges1: New developments in treatment of cancer2: A summary of molecular pathways responsible for cancer progression3: Challenges in treatment of cancer with conventional strategiesSection II: Phytochemicals and cancer therapy4: Phytochemicals in suppressing cancer proliferation5: Phytochemicals in suppressing cancer metastasis6: Phytochemicals in providing cancer therapy sensitivitySection III: Phytochemicals in the treatment of other diseases7: Phytochemicals in treatment of Diabetes mellitus8: Phytochemicals in treatment of neurological diseases9: Phytochemicals in treatment of ischemic/reperfusion injury10: Phytochemicals in treatment of infectious diseasesSection IV: Phytochemicals and cellular mechanisms in cancer therapy11: Phytochemicals in regulating glycolysis in cancer12: Phytochemicals in regulating apoptosis in cancer13: Phytochemicals in regulating autophagy in cancer14: Phytochemicals in regulating EMT and MMPs in cancerSection V: Phytochemicals and molecular pathways in cancer15: Phytochemicals in regulating STAT3 signaling in cancer16: Phytochemicals in regulating Wnt signaling in cancer17: Phytochemicals in regulating NF-kB signaling signaling in cancer18: Phytochemicals in regulating PTEN/PI3K/Akt signaling in cancer19: Phytochemicals in regulating non-coding RNAs in cancerSection VI: Nano-scale delivery systems for phytochemicals in cancer therapy20: Polymeric nanoparticles for delivery of phytochemicals in cancer therapy21: Lipid-based nanoparticles for delivery of phytochemicals in cancer therapy22: Carbon- and metal-based nanomaterials for delivery of phytochemicals in cancer therapySection VII: Clinical applications23: Application of phytochemicals in clinical trials for treatment of diseases and malignant tumors24: The market of natural products around the world

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors. Dr. Navid Rabiee, Ph.D., is a leading scientist with over 42,000 citations and an H-index of 72. He integrates molecular and cellular biology with engineering to design advanced medical systems. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. Also, he is the pioneer in developing high-gravity synthesis methods for porous (in)organic nanomaterials to follow the green chemistry principles, which led to the foundations of a new field called “Green Biomaterials”. With 300+ peer-reviewed articles in top journals (including Nature, Nature Medicine, Advanced Materials, The Lancet), 9 books, and 20+ chapters, his work advances medical treatment and sustainable practices.

• Section I: Cancer treatment and challenges1: New developments in treatment of cancer2: A summary of molecular pathways responsible for cancer progression3: Challenges in treatment of cancer with conventional strategiesSection II: Phytochemicals and cancer therapy4: Phytochemicals in suppressing cancer proliferation5: Phytochemicals in suppressing cancer metastasis6: Phytochemicals in providing cancer therapy sensitivitySection III: Phytochemicals in the treatment of other diseases7: Phytochemicals in treatment of Diabetes mellitus8: Phytochemicals in treatment of neurological diseases9: Phytochemicals in treatment of ischemic/reperfusion injury10: Phytochemicals in treatment of infectious diseasesSection IV: Phytochemicals and cellular mechanisms in cancer therapy11: Phytochemicals in regulating glycolysis in cancer12: Phytochemicals in regulating apoptosis in cancer13: Phytochemicals in regulating autophagy in cancer14: Phytochemicals in regulating EMT and MMPs in cancerSection V: Phytochemicals and molecular pathways in cancer15: Phytochemicals in regulating STAT3 signaling in cancer16: Phytochemicals in regulating Wnt signaling in cancer17: Phytochemicals in regulating NF-kB signaling signaling in cancer18: Phytochemicals in regulating PTEN/PI3K/Akt signaling in cancer19: Phytochemicals in regulating non-coding RNAs in cancerSection VI: Nano-scale delivery systems for phytochemicals in cancer therapy20: Polymeric nanoparticles for delivery of phytochemicals in cancer therapy21: Lipid-based nanoparticles for delivery of phytochemicals in cancer therapy22: Carbon- and metal-based nanomaterials for delivery of phytochemicals in cancer therapySection VII: Clinical applications23: Application of phytochemicals in clinical trials for treatment of diseases and malignant tumors24: The market of natural products around the world

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors. Dr. Navid Rabiee, Ph.D., is a leading scientist with over 42,000 citations and an H-index of 72. He integrates molecular and cellular biology with engineering to design advanced medical systems. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. Also, he is the pioneer in developing high-gravity synthesis methods for porous (in)organic nanomaterials to follow the green chemistry principles, which led to the foundations of a new field called “Green Biomaterials”. With 300+ peer-reviewed articles in top journals (including Nature, Nature Medicine, Advanced Materials, The Lancet), 9 books, and 20+ chapters, his work advances medical treatment and sustainable practices.

• Section I: Cancer treatment and challenges1: New developments in treatment of cancer2: A summary of molecular pathways responsible for cancer progression3: Challenges in treatment of cancer with conventional strategiesSection II: Phytochemicals and cancer therapy4: Phytochemicals in suppressing cancer proliferation5: Phytochemicals in suppressing cancer metastasis6: Phytochemicals in providing cancer therapy sensitivitySection III: Phytochemicals in the treatment of other diseases7: Phytochemicals in treatment of Diabetes mellitus8: Phytochemicals in treatment of neurological diseases9: Phytochemicals in treatment of ischemic/reperfusion injury10: Phytochemicals in treatment of infectious diseasesSection IV: Phytochemicals and cellular mechanisms in cancer therapy11: Phytochemicals in regulating glycolysis in cancer12: Phytochemicals in regulating apoptosis in cancer13: Phytochemicals in regulating autophagy in cancer14: Phytochemicals in regulating EMT and MMPs in cancerSection V: Phytochemicals and molecular pathways in cancer15: Phytochemicals in regulating STAT3 signaling in cancer16: Phytochemicals in regulating Wnt signaling in cancer17: Phytochemicals in regulating NF-kB signaling signaling in cancer18: Phytochemicals in regulating PTEN/PI3K/Akt signaling in cancer19: Phytochemicals in regulating non-coding RNAs in cancerSection VI: Nano-scale delivery systems for phytochemicals in cancer therapy20: Polymeric nanoparticles for delivery of phytochemicals in cancer therapy21: Lipid-based nanoparticles for delivery of phytochemicals in cancer therapy22: Carbon- and metal-based nanomaterials for delivery of phytochemicals in cancer therapySection VII: Clinical applications23: Application of phytochemicals in clinical trials for treatment of diseases and malignant tumors24: The market of natural products around the world